Bolt Biotherapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $BOLT in the last 30 days.
See all $BOLT insider activity →Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results • Cash b
Germany’s e-scooter use is rising, driven mainly by private ownership rather than rental fleets, according to GDV data. Over 80% of scooters are privately owned. Rental units fell about 10% last year, while private fleets nearly tripled over four years. Accidents rose nearly 40% to 16,496. Lime’s IPO is noted; Bird filed for bankruptcy and Tier merged with Dott.
Bolt, the ride-hailing platform, has integrated with ChatGPT so users can request rides, get price estimates, view driver arrival times, and choose pickup spots via chat. Bolt says in-app payment inside ChatGPT is planned but not available yet, with booking completed in the Bolt app. Bolt cites Accenture Research on AI use for travel planning.
Over the past 7 days, AlphAI's AI scored 3 news stories mentioning BOLT (Bolt Biotherapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 2 neutral, and 0 bearish.
Recent BOLT coverage spans financial news, technology and earnings.
Near-term focus is BDC-4182 Phase 1/2 readout timing plus cash runway, with Q2 cost and revenue trends providing context.
Bolt’s operating model appears pressured by costs, damage incidents, and tighter regulations, which can affect unit economics and funding needs.
The integration is a distribution and conversion funnel change, but the article provides no financial metrics or payment timeline beyond “coming.”
The ChatGPT integration is a product distribution upgrade that could improve conversion and reduce friction, but it is not quantified financially in the article.
This is a corporate governance/annual meeting outcome disclosure; it typically has limited direct impact on near-term fundamentals or valuation.
AlphAI scores every news story that mentions BOLT with an AI model for sentiment and relevance, and aggregates insider trades from Bolt Biotherapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update • First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected to be released with Bolt's 3Q 2026 results • Cash b
3 min readGermany’s e-scooter use is rising, driven mainly by private ownership rather than rental fleets, according to GDV data. Over 80% of scooters are privately owned. Rental units fell about 10% last year, while private fleets nearly tripled over four years. Accidents rose nearly 40% to 16,496. Lime’s IPO is noted; Bird filed for bankruptcy and Tier merged with Dott.
6 min readBolt, the ride-hailing platform, has integrated with ChatGPT so users can request rides, get price estimates, view driver arrival times, and choose pickup spots via chat. Bolt says in-app payment inside ChatGPT is planned but not available yet, with booking completed in the Bolt app. Bolt cites Accenture Research on AI use for travel planning.
3 min readBolt says it has integrated with ChatGPT so users can ask about trips in-chat, including fare estimates, route comparisons, driver arrival times, and pickup-point recommendations. Confirmed plans transfer to the Bolt app to dispatch and complete bookings. Bolt cites Accenture research on AI tool usage and plans in-chat payments later this year.
3 min readBolt Biotherapeutics, Inc. (BOLT) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001641281 0001641281 2025-05-27 2025-05-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10,
2 min readBolt Biotherapeutics, Inc. (BOLT) reported a wider-than-anticipated loss and revenue that fell short of analyst estimates for the first quarter. The company announced a loss of $0.62 per share, exceeding the average analyst estimate of a $0.57 loss, and posted revenues of $2.20 million, significantly lower than the $5.53 million expected.
3 min readBolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +26.63% and +294.36%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min readBolt Biotherapeutics (BOLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 min readU.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Thursday. Shares of Fidus Investment Corp ( NASDAQ:FDUS ) fell sharply in pre-market trading after the company priced a $100 million public offering of 6.750% notes due 2030.
3 min readBolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of +30.31% and +73.46%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 min read
